The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.
I an sure those qualified on the board recognise:
About the Code
Chartered Accountants are expected to demonstrate the highest standards of professional conduct and to take into consideration the public interest. Ethical behaviour by Chartered Accountants plays a vital role in ensuring public trust in financial reporting and business practices and upholding the reputation of the accountancy profession.
The Code helps our members meet these obligations by providing them with ethical guidance.
As I see it, there are at least 3 chartered accountants on the main board. Although only one is acting in a professional capacity I believe that the various accountancy bodies ethics required of these persons apply to them all.. I think at the moment with some insiders involved in the various takeover talks the board should look again at investors relations as the drop in price since IPO is frightening.
From today’s Telegraph:
A BRITISH biotech start-up has raised £15m to develop rapid PCR tests which can diagnose whether people have Covid, the flu or a cold.
QuantuMDx has secured the cash from Hong Kong venture capital firm Vita Spring, coming just eight months after it raised £11m in a round which included the Government’s Future Fund.
It develops 30-minute tests used to spot Covid outbreaks on UK film sets and offices, not yet available on the NHS. By next year, the Newcastle-based company expects to have developed new tests which can detect other viruses such as the flu or respiratory syncytial virus, in addition to Covid.
Jonathan O’Halloran, chief executive, said there had been a shift during the pandemic toward a willingness among people to do regular testing and take measures to prevent the spread of any virus. He said: “People are now taking control of their own healthcare and testing themselves more and more. It’s a behavioural change.
“People used to soldier on and go to work with a cold, but now they know it’s easy to pass on viruses, so they test themselves. There’s more acceptance of testing, which is great for our industry and the next pandemic.”
Perhaps Sanofi have spare cash to buy us!
Press Release
Source: Sanofi (EURONEXT: SAN) (NASDAQ: SNY)
Sanofi to acquire Kadmon to further strengthen growth of transplant business
? Adds RezurockTM (belumosudil) an FDA-approved, first-in-class treatment for adult and pediatric patients 12 years and older with chronic graft-versus-host disease (cGVHD) after failure of at least two prior lines of systemic therapy
PARIS and NEW YORK – September 8, 2021 – Sanofi has entered into a definitive merger agreement with Kadmon Holdings, Inc. (NASDAQ: KDMN) a biopharmaceutical company that discovers, develops, and markets transformative therapies for disease areas of significant unmet medical needs. The acquisition supports Sanofi’s strategy to continue to grow its General Medicines core assets and will immediately add RezurockTM(belumosudil) to its transplant portfolio. Rezurock is a recently FDA-approved, first-in-class treatment for chronic graft-versus-host disease (cGVHD) for adult and pediatric patients 12 years and older who have failed at least two prior lin
I would hope that, if Mandy is earning her salary and doing her job properly, she will be keeping up to date with this BB and informing the Board of the upcoming questions. They should therefore be well prepared for the feelings of discomfort of many shareholders BUT whether any answers to these questions will be forthcoming on Wednesday is doubtful? Anyway, Porky, you have done a sterling job - well done!
CORONAVIRUS
Share
Virus here to stay so halt mass testing, says expert
Sarah KnaptonSCIENCE EDITOR
THE delta variant of Covid has wrecked any chance of herd immunity, a panel of experts including the head of the Oxford vaccine team has said, as they called for an end to mass testing so that Britain can start to live with the virus.
Scientists said it was time to accept that there is no way of stopping the virus spreading through the entire population, and monitoring people with mild symptoms was no longer helpful.
image
Prof Sir Andrew Pollard, who led the Oxford vaccine team, said it was clear that the delta variant can still infect people who have been vaccinated, which made herd immunity impossible to reach, even with the UK’s high uptake.
Yesterday, the Department of Health confirmed that more than three quarters of adults have received both jabs, and calculated that 60,000 deaths and 66,900 hospitalisations have been prevented by the vaccines.
However, experts said it would never be enough to stop the virus spreading.
Speaking to the all-party parliamentary group on coronavirus, Sir Andrew said: “Anyone who is still unvaccinated will, at some point, meet the virus.
“We don’t have anything that will stop transmission, so I think we are in a situation where herd immunity is not a possibility, and I suspect the virus will throw up a new variant that is even better at infecting vaccinated individuals.”
Until recently, it was hoped that increasing the number of Britons jabbed would create a ring of protection around the population.
How doe this affect us?
Blow to Oxford Nanopore after early end to £113m Covid testing contract
Hannah Boland
BRITAIN’s brightest biotech firm, Oxford Nanopore, has been dealt a blow after the Government ended a £113m contract for its Covid tests early, despite praising the test’s “life-saving innovations”.
£113m
The total value of the test kits contract with biotech firm Oxford Nanopore, which the Government has decided to end
In filings on Companies House, Oxford Nanopore said the Department of Health had decided against taking all the Covid tests it had agreed to buy.
Oxford Nanopore did not disclose how many tests the Government had signed up for but ministers paid £113m for the kits, suggesting a significant order size. Part of the order was fulfilled. Its 90-minute tests use saliva to tell whether someone has Covid and do not require swabs, making them easier and quicker to conduct.
In the depths of the pandemic, Oxford Nanopore’s tests had been deemed a “life-saving innovation” by then Health Secretary Matt Han****.
Last August, he said the tests formed a key pillar of the UK’s efforts to “break chains of transmission quickly” providing on-the-spot results for people in care homes and hospitals. However, Oxford Nanopore revealed that, in April, the Department of Health determined that it “no longer had a requirement for our product” because the vaccination rollout meant fewer people needed testing, and it ended the contract before taking full delivery.
The deal would have provided a major boost to Oxford Nanopore’s revenues ahead of its blockbuster London listing expected later this year.
Analysts have suggested the company could be priced anywhere between £4.5bn and £16bn, putting it among the most valuable floats in the City’s history and coming as a boon for the London Stock Exchange, which has been desperate to attract more biotech leaders. Despite the Government contract ending early, Oxford Nanopore expected revenues to keep rising this year with other contracts already agreed.
It comes after a stellar year for Nanopore, which also makes DNA sequencing tools that can track Covid mutations and which have been used for a fifth of all Covid sequencing globally.
Revenues last year hit £114m – more than double the £52m for 2019. Even stripping out the Covid bump from last year, Oxford Nanopore’s revenue was up 26pc compared to a market that contracted by 7pc. Losses also narrowed in 2020 by £11m to £61m
A spokesman for Oxford Nanopore said: “We developed LamPORE, a scalable, gold-standard performance Covid test, in the early stages of the pandemic.
“It was clearly good news as we went into spring 2021 to see the requirement for Covid testing in the UK was much reduced. We continue to provide technology around the world for Covid sequencing, in addition to our core business of sequencing.”
iIs this who we are talking about?
https://forbetterscience.com/2019/07/15/questionable-activities-of-uk-company-celixir-by-patricia-murray/
Telegraph’s coverage where last paragraphs not hopeful?!
http://digitaleditions.telegraph.co.uk/data/629/reader/reader.html?social#!preferred/0/package/629/pub/629/page/92/article/185007